A Multicenter Randomized Double-Blinded Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
The purpose of this research study is to investigate the safety and how well inhaled treprostinil works in subjects with pulmonary hypertension (PH) associated with interstitial lung disease (ILD) or combined pulmonary fibrosis and emphysema (CPFE).
The purpose of this study is to investigate the safety and how well inhaled treprostinil works in subjects with WHO Group 3 PH.
- IRB Number: 1602009422
- Research Study Identifier: TX6365
- Principal Investigator: William Harvey, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required